Mesoblast (NASDAQ:MESO) Sees Large Volume Increase – Still a Buy?

Mesoblast Limited (NASDAQ:MESO) saw unusually-high trading volume on Friday . Approximately 419,400 shares were traded during trading, a decline of 21% from the previous session’s volume of 532,140 shares.The stock last traded at $17.18 and had previously closed at $17.90.

Analyst Upgrades and Downgrades

MESO has been the topic of a number of recent analyst reports. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Tuesday, September 24th. Finally, Piper Sandler increased their price objective on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Stock Performance

The company’s fifty day moving average price is $13.25 and its 200-day moving average price is $9.47. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MESO. GAMMA Investing LLC grew its holdings in shares of Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after buying an additional 1,213 shares during the last quarter. Perkins Coie Trust Co grew its stake in Mesoblast by 15.0% during the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares during the period. Lazari Capital Management Inc. raised its stake in shares of Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the last quarter. Finally, Rathbones Group PLC acquired a new stake in shares of Mesoblast during the second quarter worth about $95,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.